Cargando…
Identification of activating enzymes of a novel FBPase inhibitor prodrug, CS-917
CS-917 (MB06322) is a selective small compound inhibitor of fructose 1,6-bisphosphatase (FBPase), which is expected to be a novel drug for the treatment of type 2 diabetes by inhibiting gluconeogenesis. CS-917 is a bisamidate prodrug and activation of CS-917 requires a two-step enzyme catalyzed reac...
Autores principales: | Kubota, Kazuishi, Inaba, Shin-ichi, Nakano, Rika, Watanabe, Mihoko, Sakurai, Hidetaka, Fukushima, Yumiko, Ichikawa, Kimihisa, Takahashi, Tohru, Izumi, Takashi, Shinagawa, Akira |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4492754/ https://www.ncbi.nlm.nih.gov/pubmed/26171222 http://dx.doi.org/10.1002/prp2.138 |
Ejemplares similares
-
Identification of a Metabolizing Enzyme in Human Kidney by Proteomic Correlation Profiling
por: Sakurai, Hidetaka, et al.
Publicado: (2013) -
Targeting FBPase is an emerging novel approach for cancer therapy
por: Liu, Gao-Min, et al.
Publicado: (2018) -
Purification and Identification of Activating Enzymes of CS-0777, a Selective Sphingosine 1-Phosphate Receptor 1 Modulator, in Erythrocytes
por: Yonesu, Kiyoaki, et al.
Publicado: (2011) -
Toward the Prediction of FBPase Inhibitory Activity Using Chemoinformatic Methods
por: Hao, Ming, et al.
Publicado: (2012) -
Citrate targets FBPase and constitutes an emerging novel approach for cancer therapy
por: Icard, Philippe, et al.
Publicado: (2018)